Patients with mutations in the DDR response genes BRCA2, ATM, and BRCA1 reported significantly greater response rates to olaparib than noncarriers in one of the earliest trials of PARPi in patients with advanced PCa (Gurley and Kemp, 2001). The gene discussed is BRCA1; the disease is posterior cortical atrophy.